About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(tetO-Esr1)#Paf
transgene insertion, Priscilla A Furth
MGI:5296756
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB MGI:5297135
cx2
Tg(MMTVtTA)1Mam/0
Tg(tetO-Esr1)#Paf/0
involves: C57BL/6 * FVB/N * SJL MGI:5296757
cx3
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
involves: FVB/N MGI:5296806


Genotype
MGI:5297135
cn1
Allelic
Composition
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+
Genetic
Background
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm2Cxd mutation (1 available); any Brca1 mutation (75 available)
Tg(MMTV-cre)4Mam mutation (1 available)
Tg(MMTV-rtTA)1Lach mutation (0 available)
Tg(tetO-Esr1)#Paf mutation (0 available)
Trp53tm1Brd mutation (6 available); any Trp53 mutation (145 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mutants develop hyperplastic alveolar nodules
• 100% of mutants develop invasive mammary cancer
• some cancers are Esr1-negative while others are Esr1-positive

neoplasm
• 100% of mutants develop invasive mammary cancer
• some cancers are Esr1-negative while others are Esr1-positive
• mutants develop mammary gland preneoplasia
• some preneoplasia are Esr1-negative while others are Esr1-positive

integument
• mutants develop hyperplastic alveolar nodules
• 100% of mutants develop invasive mammary cancer
• some cancers are Esr1-negative while others are Esr1-positive




Genotype
MGI:5296757
cx2
Allelic
Composition
Tg(MMTVtTA)1Mam/0
Tg(tetO-Esr1)#Paf/0
Genetic
Background
involves: C57BL/6 * FVB/N * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(MMTVtTA)1Mam mutation (1 available)
Tg(tetO-Esr1)#Paf mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls

reproductive system
• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls
• when 14 week old males are removed from doxycycline administration for 50 days, epididymis weight is decreased compared to controls
• when 14 week old males are removed from doxycycline administration for 50 days, vas deferens weight is decreased compared to controls
• females raised on doxycycline to block expression of Esr1 exhibit a decrease in the number of days in estrus when the doxycycline is removed and Esr1 is expressed, however overall cycle length is no different from controls
• mutants without doxycycline (expressing Esr1) exhibit a 15% reduction in litter size compared to mutants receiving doxycycline




Genotype
MGI:5296806
cx3
Allelic
Composition
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
• rates of mammary epithelial cell proliferation are increased compared to controls
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
• 52% of mutants at 4 months of age show lobular hyperplasia
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

neoplasm
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

integument
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
• rates of mammary epithelial cell proliferation are increased compared to controls
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
• 52% of mutants at 4 months of age show lobular hyperplasia
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

Mouse Models of Human Disease
OMIM ID Ref(s)
Breast Cancer 114480 J:96383





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/17/2016
MGI 6.05
The Jackson Laboratory